drugset / Trial / NCT07434180
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Phase 2
Not yet recruiting
20 enrolled
Peter MacCallum Cancer Centre, Australia
National Health and Medical Research Council, Australia · collabNovartis · collabSOFIE · collabUniversity of Melbourne · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).
Timeline
- Start
- 2026-06
- Primary completion
- 2030-06
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-FAP-2286 | Unknown | 9250 mbq | — |